Evolving Strategies for Target Selection for Antibody-Drug Conjugates

Curative Properties of Noninternalizing Antibody-Drug Conjugates Based on Maytansinoids

(2014) E. Perrino et al.   CANCER RESEARCH

Abstract C238: Polyacetal polymer-based anti-HER2 antibody-drug conjugate employing cysteine bioconjugation through thioether linkage allows a high drug loading of dolastatin-derived payload with excellent pharmacokinetics and potent anti-tumor activity.

(2014) J. Thomas et al.   MOLECULAR CANCER THERAPEUTICS

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody-Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

(2014) S. Golfier et al.   MOLECULAR CANCER THERAPEUTICS

A draft map of the human proteome

(2014) Min-Sik Kim et al.   NATURE

Small Targeted Cytotoxics: Current State and Promises from DNA-Encoded Chemical Libraries

(2013) Nikolaus Krall et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Location Matters: Site of Conjugation Modulates Stability and Pharmacokinetics of Antibody Drug Conjugates

(2013) Pavel Strop et al.   CHEMISTRY & BIOLOGY

Pertuzumab Protects the Achilles' Heel of Trastuzumab--Emtansine

(2013) W. R. Gwin et al.   CLINICAL CANCER RESEARCH

Dual Targeting of HER2-Positive Cancer with Trastuzumab Emtansine and Pertuzumab: Critical Role for Neuregulin Blockade in Antitumor Response to Combination Therapy

(2013) G. D. L. Phillips et al.   CLINICAL CANCER RESEARCH

Phase II Randomized Study of Trastuzumab Emtansine Versus Trastuzumab Plus Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer

(2013) Sara A. Hurvitz et al.   JOURNAL OF CLINICAL ONCOLOGY

Site-specific antibody drug conjugates for cancer therapy

(2013) Siler Panowski et al.   mAbs

The Cancer Genome Atlas Pan-Cancer analysis project

(2013) John N Weinstein et al.   NATURE GENETICS

The Genotype-Tissue Expression (GTEx) project

(2013) John Lonsdale et al.   NATURE GENETICS

Maturing antibody–drug conjugate pipeline hits 30

(2013) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Antibody-Based Delivery of Interleukin-2 to Neovasculature Has Potent Activity Against Acute Myeloid Leukemia

(2013) K. L. Gutbrodt et al.   Science Translational Medicine

An integrated approach to identify normal tissue expression of targets for antibody-drug conjugates: case study of TENB2

(2012) C Andrew Boswell et al.   BRITISH JOURNAL OF PHARMACOLOGY

Antigen Shedding May Improve Efficiencies for Delivery of Antibody-Based Anticancer Agents in Solid Tumors

(2012) Y. Pak et al.   CANCER RESEARCH

Clinical Binding Properties, Internalization Kinetics, and Clinicopathologic Activity of Brentuximab Vedotin: An Antibody-Drug Conjugate for CD30-Positive Lymphoid Neoplasms

(2012) Jonathan R. Fromm et al.   Clinical Lymphoma Myeloma & Leukemia

Evaluation of MVA-5T4 as a novel immunotherapeutic vaccine in colorectal, renal and prostate cancer

(2012) Robert J Amato et al.   Future Oncology

CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein

(2012) Owen J. McGinn et al.   JOURNAL OF CELL SCIENCE

A Phase II Study of Trastuzumab Emtansine in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer Who Were Previously Treated With Trastuzumab, Lapatinib, an Anthracycline, a Taxane, and Capecitabine

(2012) Ian E. Krop et al.   JOURNAL OF CLINICAL ONCOLOGY

Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study

(2012) Barbara Pro et al.   JOURNAL OF CLINICAL ONCOLOGY

Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma

(2012) Anas Younes et al.   JOURNAL OF CLINICAL ONCOLOGY

Long-term Tumor Regression Induced by an Antibody-Drug Conjugate That Targets 5T4, an Oncofetal Antigen Expressed on Tumor-Initiating Cells

(2012) P. Sapra et al.   MOLECULAR CANCER THERAPEUTICS

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

(2012) Jordi Barretina et al.   NATURE

Trastuzumab Emtansine for HER2-Positive Advanced Breast Cancer

(2012) Sunil Verma et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Traceless Vascular-Targeting Antibody-Drug Conjugate for Cancer Therapy

(2011) Gonçalo J. L. Bernardes et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Delineation of a Cellular Hierarchy in Lung Cancer Reveals an Oncofetal Antigen Expressed on Tumor-Initiating Cells

(2011) M. Damelin et al.   CANCER RESEARCH

Waif1/5T4 Inhibits Wnt/β-Catenin Signaling and Activates Noncanonical Wnt Pathways by Modifying LRP6 Subcellular Localization

(2011) Birgit Kagermeier-Schenk et al.   DEVELOPMENTAL CELL

An antibody–cytotoxic conjugate, BIIB015, is a new targeted therapy for Cripto positive tumours

(2011) Rebecca K. Kelly et al.   EUROPEAN JOURNAL OF CANCER

Investigational antibody drug conjugates for solid tumors

(2011) Puja Sapra et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

The quantitative proteome of a human cell line

(2011) M. Beck et al.   Molecular Systems Biology

Global quantification of mammalian gene expression control

(2011) Björn Schwanhäusser et al.   NATURE

Integrin activation and internalization on soft ECM as a mechanism of induction of stem cell differentiation by ECM elasticity

(2011) J. Du et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Phase II Study of the Antibody Drug Conjugate Trastuzumab-DM1 for the Treatment of Human Epidermal Growth Factor Receptor 2 (HER2) –Positive Breast Cancer After Prior HER2-Directed Therapy

(2010) Howard A. Burris et al.   JOURNAL OF CLINICAL ONCOLOGY

Naptumomab Estafenatox, an Engineered Antibody-superantigen Fusion Protein With Low Toxicity and Reduced Antigenicity

(2010) Göran Forsberg et al.   JOURNAL OF IMMUNOTHERAPY

Antibody drug-conjugates targeting the tumor vasculature

(2010) Hans-Peter Gerber et al.   mAbs

CXCR4 Mediated Chemotaxis Is Regulated by 5T4 Oncofetal Glycoprotein in Mouse Embryonic Cells

(2010) Thomas D. Southgate et al.   PLoS One

A novel reactive ester derivative of biotin with reduced membrane permeability for in vivo biotinylation experiments

(2010) Verena Strassberger et al.   PROTEOMICS

Expression of the oncofetal ED-B-containing fibronectin isoform in hematologic tumors enables ED-B-targeted 131I-L19SIP radioimmunotherapy in Hodgkin lymphoma patients

(2009) S. Sauer et al.   BLOOD

CEACAM5-Targeted Therapy of Human Colonic and Pancreatic Cancer Xenografts with Potent Labetuzumab-SN-38 Immunoconjugates

(2009) S. V. Govindan et al.   CLINICAL CANCER RESEARCH

Mutations and Response to Epidermal Growth Factor Receptor Inhibitors

(2009) P. Laurent-Puig et al.   CLINICAL CANCER RESEARCH

Antibody-Drug Conjugate Targets

(2009) B. Teicher   CURRENT CANCER DRUG TARGETS

KitK641E oncogene up-regulatesSprouty homolog 4andTrophoblast glycoproteinin interstitial cells of Cajal in a murine model of gastrointestinal stromal tumours

(2009) Petra Gromova et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Tumour-initiating cells: challenges and opportunities for anticancer drug discovery

(2009) Bin-Bing S. Zhou et al.   NATURE REVIEWS DRUG DISCOVERY

Effective Immunoconjugate Therapy in Cancer Models Targeting a Serine Protease of Tumor Fibroblasts

(2008) E. Ostermann et al.   CLINICAL CANCER RESEARCH

Caveolin-1-dependent  1 integrin endocytosis is a critical regulator of fibronectin turnover

(2008) F. Shi et al.   JOURNAL OF CELL SCIENCE

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

(2008) Jagath R Junutula et al.   NATURE BIOTECHNOLOGY

RNA-Seq: a revolutionary tool for transcriptomics

(2008) Zhong Wang et al.   NATURE REVIEWS GENETICS